Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer

Background In designing phase III randomized clinical trials (RCTs), the expected magnitude of the benefit of the experimental therapy (delta) determines the number of patients required and the number of person-years of follow-up. We conducted a systematic review to evaluate how reliably delta approximates the observed benefit (B) in RCTs that evaluated cancer treatment. Methods RCTs evaluating systemic therapy in adult cancer patients published in 10 journals from January 1, 2005, through December 31, 2009, were identified. Data were extracted from each publication independently by two investigators. The related-samples Sign test was used to determine whether the median difference between d and B was statistically significant in different study subsets and was two-sided. Results A total of 253 RCTs met the eligibility criteria and were included in the analysis. Regardless of whether benefit was defined as proportional change (median difference between delta and B = -13.0%, 95% confidence interval [CI] = -21.0% to -8.0%), absolute change (median difference between delta and B = -8.0%, 95% CI = -9.9% to -5.1%), ;or median increase in a time-to-event endpoint (median difference between delta and B = -1.4 months, 95% CI = -2.1 to -0.8 months), delta was consistently and statistically significantly larger than B (P < .001, for each, respectively). This relationship between delta and B was independent of year of publication, industry funding, management by cooperative trial groups, type of control arm, type of experimental arm, disease site, adjuvant treatment, or treatment for advanced disease, and likely contributed to the high proportion of negative RCTs (158 [62.5%] of 253 studies). Conclusions Investigators consistently make overly optimistic assumptions regarding treatment benefits when designing RCTs. Attempts to reduce the number of negative RCTs should focus on more realistic estimations of delta. Increased use of interim analyses, certain adaptive trial designs, and better biological characterization of patients are potential ways of mitigating this problem. J Natl Cancer Inst 2012;104:590-598